OR WAIT null SECS
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
February 12, 2024
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
February 07, 2024
Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.
February 05, 2024
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
February 02, 2024
The milestone approval of a gene-edited therapeutic paves the way for gene-editing technologies.
January 24, 2024
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
January 22, 2024
Abzena has launched its AbZelect platforms, designed for improving cell line development.
December 20, 2023
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.
December 08, 2023
MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.